Oberweis Asset Management Inc. Purchases New Stake in Champions Oncology Inc (CSBR)
Oberweis Asset Management Inc. purchased a new stake in Champions Oncology Inc (NASDAQ:CSBR) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 37,233 shares of the biotechnology company’s stock, valued at approximately $291,000. Oberweis Asset Management Inc. owned 0.32% of Champions Oncology as of its most recent SEC filing.
A number of other hedge funds have also modified their holdings of CSBR. BlackRock Inc. purchased a new position in Champions Oncology in the 2nd quarter valued at approximately $104,000. Sandy Spring Bank purchased a new position in Champions Oncology in the 4th quarter valued at approximately $205,000. Alambic Investment Management L.P. purchased a new position in Champions Oncology in the 4th quarter valued at approximately $215,000. Northern Trust Corp boosted its position in Champions Oncology by 7.9% in the 4th quarter. Northern Trust Corp now owns 27,730 shares of the biotechnology company’s stock valued at $217,000 after buying an additional 2,028 shares during the period. Finally, Bank of Montreal Can purchased a new position in Champions Oncology in the 3rd quarter valued at approximately $250,000. 52.59% of the stock is owned by institutional investors.
Several equities analysts have commented on CSBR shares. National Securities started coverage on shares of Champions Oncology in a research report on Wednesday, February 27th. They issued a “buy” rating and a $17.00 price target for the company. Zacks Investment Research cut shares of Champions Oncology from a “hold” rating to a “strong sell” rating in a research report on Friday, December 21st. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $12.75.
Champions Oncology stock opened at $10.13 on Friday. The firm has a market cap of $117.85 million, a PE ratio of -72.36 and a beta of 1.54. Champions Oncology Inc has a 12-month low of $3.25 and a 12-month high of $17.90. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.94 and a quick ratio of 0.94.
Champions Oncology (NASDAQ:CSBR) last released its quarterly earnings data on Monday, December 17th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.04 by ($0.01). The firm had revenue of $6.69 million for the quarter, compared to analysts’ expectations of $6.35 million. Champions Oncology had a return on equity of 1.44% and a net margin of 0.05%. As a group, sell-side analysts forecast that Champions Oncology Inc will post 0.12 earnings per share for the current year.
About Champions Oncology
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Further Reading: What is a Stop Order?
Want to see what other hedge funds are holding CSBR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Champions Oncology Inc (NASDAQ:CSBR).
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.